Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A multi-institutional study of the impact of the COVID-19 pandemic on pancreatic cancer diagnosis and management.
Authors
Claudia Rosso
University of California, Irvine, School of Medicine, Irvine, CA
Claudia Rosso , Jennifer B. Valerin , Parisa Oviedo , Niloofar Radgoudarzi , Wen-Pin Chen , Christine E. McLaren , Rebekah Ruth White , Jason Zell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Impact of COVID-19
DOI
10.1200/JCO.2022.40.4_suppl.526
Abstract #
526
Poster Bd #
E8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase 2 randomized study of rintatolimod following FOLFIRINOX in patients with locally advanced pancreatic adenocarcinoma.
First Author: Kelsey Klute
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Characterizing the genomic landscape of locally advanced pancreatic cancer.
First Author: Galileo Arturo Gonzalez Conchas
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Trends in incidence and survival of early-stage pancreatic ductal adenocarcinoma in the United States.
First Author: Gerardo Perrotta
Poster
2023 ASCO Gastrointestinal Cancers Symposium
nITRO: A phase 2 study of perioperative liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) in patients with resectable pancreatic ductal adenocarcinoma (rPDAC).
First Author: Davide Melisi